
The combination of doxorubicin HCl liposome injection (Doxil, Ortho Biotech) and bortezomib (Velcade, Millennium/Johnson & Johnson) has been granted FDA approval for treating patients with multiple myeloma who have received at least one prior therapy but have not received earlier treatment with bortezomib.
